SCHEMBL18856431

SCHEMBL18856431

Cc1nc2cc(-c3ccc(Cl)cc3)ccc2s1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HSD17B10 Q99714 2/20 0.50
ALDH1A1 P00352 2/20 0.50
TP53 P04637 1/20 0.50
MAPT P10636 1/20 0.50
PKM P14618 1/20 0.50
HPGD P15428 1/20 0.50
GAA P10253 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
KMT2A Q03164 1/20 0.45
PIK3CD O00329 1/20 0.45
PIK3CA P42336 1/20 0.45
PIK3CB P42338 1/20 0.45
PIK3CG P48736 1/20 0.45
POLB P06746 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.42
IDO1 P14902 1/20 0.42
GRM1 Q13255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12810173 0.86 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL1049510 0.85 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL29361355 0.85 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL6196778 0.84 NPC1 (0.56) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL13394502 0.83 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL1849993 0.83 NPC1 (0.54) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL13862697 0.83 TRPV1 (0.52) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL23114373 0.82 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
Iodomethane SCHEMBL28083731 0.82 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL14864453 0.82 KMT2A (0.52) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170136007-A1 NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF THE FEINSTEIN INST MEDICAL RES (US) 2017-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170136007-A1 NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF CHRNA7, CHRNA5, CHRM5 SMN1; SMN2 468/4885NPC1 2069/4885RAB9A 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.